<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35316152</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1555-8576</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cancer biology &amp; therapy</Title>
          <ISOAbbreviation>Cancer Biol Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>MiR-376a-3p increases cell apoptosis in acute myeloid leukemia by targeting MT1X.</ArticleTitle>
        <Pagination>
          <StartPage>234</StartPage>
          <EndPage>242</EndPage>
          <MedlinePgn>234-242</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/15384047.2022.2054243</ELocationID>
        <Abstract>
          <AbstractText>Metallothioneins (MTs) are a group of low-molecular weight cysteine-rich proteins that play vital roles in oxidative stress, metal homeostasis, carcinogenesis and drug resistance. However, few studies have analyzed the roles of MTs in acute myeloid leukemia (AML). In this study, we revealed that the expression of metallothionein1X (MT1X), a main isoform of MTs, was highly expressed and acted as a candidate of prognostic indicator in AML patients. In vitro cell function experiments verified that silencing MT1X inhibited the proliferation of AML cells, sensitized cells to doxorubicin, and increased their apoptosis. We also showed that the downregulation of MT1X expression suppressed nuclear factor-κB (NF-κB) signaling by reducing p65, p-IκB-α, and downstream effectors. Elevated p65 and MT1X levels were indicators in AML. Moreover, we revealed that miR-376a-3p had binding sites with 3'-UTR of MT1X, suggesting that MT1X was negatively regulated by miR-376a-3p. Cell functional assay results indicated that miR-376a-3p overexpression significantly inhibited the proliferation, arrested the AML cells in the G0/G1 phase and induced cell apoptosis. The rescue experiments further confirmed that miR-376a-3p could reverse the promotion of MT1X overexpression on the progress of AML cells. Taken together, our results revealed that elevated MT1X expression might be involved in the mechanism underlying AML progression, indicating that the miR-376a/MT1X axis might serve as a promising novel target for the effective treatment of patients with AML.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xin</LastName>
            <ForeName>Xiangke</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0001-5968-9947</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Xinyang Hospital Affiliated to Zhengzhou University, Xinyang, Henan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Zheng</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Xinyang Hospital Affiliated to Zhengzhou University, Xinyang, Henan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Jia</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-6435-9368</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yicheng</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0003-4300-0900</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cancer Biol Ther</MedlineTA>
        <NlmUniqueID>101137842</NlmUniqueID>
        <ISSNLinking>1538-4047</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020413">3' Untranslated Regions</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000718202">MIRN376A1 microRNA, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D020413" MajorTopicYN="N">3' Untranslated Regions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015470" MajorTopicYN="Y">Leukemia, Myeloid, Acute</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">AML</Keyword>
        <Keyword MajorTopicYN="Y">apoptosis</Keyword>
        <Keyword MajorTopicYN="Y">metallothionein 1X</Keyword>
        <Keyword MajorTopicYN="Y">miR-376a-3p</Keyword>
        <Keyword MajorTopicYN="Y">proliferation</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>17</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35316152</ArticleId>
        <ArticleId IdType="pmc">PMC8942499</ArticleId>
        <ArticleId IdType="doi">10.1080/15384047.2022.2054243</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lowenberg B, Downing JR, Burnett A.. 
Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051–1062. doi:10.1056/NEJM199909303411407. PMID: 10502596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199909303411407</ArticleId>
            <ArticleId IdType="pubmed">10502596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381(9865):484–495. doi:10.1016/S0140-6736(12)61727-9. PMID: 23399072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(12)61727-9</ArticleId>
            <ArticleId IdType="pubmed">23399072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coyle P, Philcox JC, Carey LC, Rofe AM. Metallothionein: the multipurpose protein. Cell Mol Life Sci. 2002;59(4):627–647. doi:10.1007/s00018-002-8454-2. PMID: 12022471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-002-8454-2</ArticleId>
            <ArticleId IdType="pubmed">12022471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pedersen MO, Larsen A, Stoltenberg M, Penkowa M. The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem. 2009;44(1):29–64. doi:10.1016/j.proghi.2008.10.001. PMID: 19348910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.proghi.2008.10.001</ArticleId>
            <ArticleId IdType="pubmed">19348910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duerr GD, Dewald D, Schmitz EJ, Verfuerth L, Keppel K, Peigney C, Ghanem A, Welz A, Dewald O. Metallothioneins 1 and 2 Modulate Inflammation and Support Remodeling in Ischemic Cardiomyopathy in Mice. Mediators Inflamm. 2016;2016:7174127. doi:10.1155/2016/7174127. PMID: 27403038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2016/7174127</ArticleId>
            <ArticleId IdType="pmc">PMC4923606</ArticleId>
            <ArticleId IdType="pubmed">27403038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ugajin T, Nishida K, Yamasaki S, Suzuki J, Mita M, Kubo M, Yokozeki H, Hirano T. Zinc-binding metallothioneins are key modulators of IL-4 production by basophils. Mol Immunol. 2015;66(2):180–188. doi:10.1016/j.molimm.2015.03.002. PMID: 25801306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molimm.2015.03.002</ArticleId>
            <ArticleId IdType="pubmed">25801306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tiwari R, Pandey SK, Goel S, Bhatia V, Shukla S, Jing X, Dhanasekaran SM, Ateeq B. SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression. Oncogenesis. 2015;4:e162. doi:10.1038/oncsis.2015.23. PMID: 26258891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/oncsis.2015.23</ArticleId>
            <ArticleId IdType="pmc">PMC4632074</ArticleId>
            <ArticleId IdType="pubmed">26258891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan DW, Fan JW, Yu ZH, Li MX, Wen YG, Li DW, Zhou CZ, Wang XL, Wang Q, Tang HM, et al. Downregulation of metallothionein 1F, a putative oncosuppressor, by loss of heterozygosity in colon cancer tissue. Biochim Biophys Acta. 2012;1822(6):918–926. 10.1016/j.bbadis.2012.02.021. PMID: 22426038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2012.02.021</ArticleId>
            <ArticleId IdType="pubmed">22426038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yap X, Tan HY, Huang J, Lai Y, Yip GW, Tan PH, Bay BH. Over-expression of metallothionein predicts chemoresistance in breast cancer. J Pathol. 2009;217(4):563–570. doi:10.1002/path.2489. PMID: 19116991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.2489</ArticleId>
            <ArticleId IdType="pubmed">19116991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arriaga JM, Greco A, Mordoh J, Bianchini M. Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy. Mol Cancer Ther. 2014;13(5):1369–1381. doi:10.1158/1535-7163.MCT-13-0944. PMID: 24634414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-13-0944</ArticleId>
            <ArticleId IdType="pubmed">24634414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z, Ye Q, Wu L, Gao F, Xie H, Zhou L, Zheng S, Xu X. Metallothionein 1 family profiling identifies MT1X as a tumor suppressor involved in the progression and metastatic capacity of hepatocellular carcinoma. Mol Carcinog. 2018;57(11):1435–1444. doi:10.1002/mc.22846. PMID: 29873415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mc.22846</ArticleId>
            <ArticleId IdType="pubmed">29873415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng B, Gu Y, Xiong Y, Zheng G, He Z. Microarray-assisted pathway analysis identifies MT1X &amp; NFkappaB as mediators of TCRP1-associated resistance to cisplatin in oral squamous cell carcinoma. PLoS One. 2012;7(12):e51413. doi:10.1371/journal.pone.0051413. PMID: 23251525.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0051413</ArticleId>
            <ArticleId IdType="pmc">PMC3519677</ArticleId>
            <ArticleId IdType="pubmed">23251525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duval D, Trouillas M, Thibault C, Dembele D, Diemunsch F, Reinhardt B, Mertz AL, Dierich A, Boeuf H. Apoptosis and differentiation commitment: novel insights revealed by gene profiling studies in mouse embryonic stem cells. Cell Death Differ. 2006;13(4):564–575. doi:10.1038/sj.cdd.4401789. PMID: 16311515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.cdd.4401789</ArticleId>
            <ArticleId IdType="pubmed">16311515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maghdooni Bagheri P, Rahman MT, Van Soest S, De Ley M. Differential quantitative zinc-induced expression of human metallothionein isogenes in haematopoietic precursor cell lines. J Trace Elem Med Biol. 2009;23(2):124–131. doi:10.1016/j.jtemb.2009.02.003. PMID: 19398060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtemb.2009.02.003</ArticleId>
            <ArticleId IdType="pubmed">19398060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maghdooni Bagheri P, Govaerts I, De Ley M. Role of metallothionein in differentiation of leukemia cells. Mol Biol Rep. 2011;38(5):3017–3022. doi:10.1007/s11033-010-9967-7. PMID: 20127519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11033-010-9967-7</ArticleId>
            <ArticleId IdType="pubmed">20127519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sauerbrey A, Zintl F, Hermann J, Volm M. Multiple resistance mechanisms in acute nonlymphoblastic leukemia (ANLL). Anticancer Res. 1998;18(2B):1231–1236. PMID: 9615793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9615793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imoto A, Okada M, Okazaki T, Kitasato H, Harigae H, Takahashi S. Metallothionein-1 isoforms and vimentin are direct PU.1 downstream target genes in leukemia cells. J Biol Chem. 2010;285(14):10300–10309. doi:10.1074/jbc.M109.095810. PMID: 20139074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M109.095810</ArticleId>
            <ArticleId IdType="pmc">PMC2856235</ArticleId>
            <ArticleId IdType="pubmed">20139074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Si M, Lang J. The roles of metallothioneins in carcinogenesis. J Hematol Oncol. 2018;11(1):107. doi:10.1186/s13045-018-0645-x. PMID: 30139373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-018-0645-x</ArticleId>
            <ArticleId IdType="pmc">PMC6108115</ArticleId>
            <ArticleId IdType="pubmed">30139373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdel-Mageed AB, Agrawal KC. Activation of nuclear factor kappaB: potential role in metallothionein-mediated mitogenic response. Cancer Res. 1998;58(11):2335–2338. PMID: 9622069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9622069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganger R, Garla R, Mohanty BP, Bansal MP, Garg ML. Protective Effects of Zinc Against Acute Arsenic Toxicity by Regulating Antioxidant Defense System and Cumulative Metallothionein Expression. Biol Trace Elem Res. 2016;169(2):218–229. doi:10.1007/s12011-015-0400-x. PMID: 26113309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12011-015-0400-x</ArticleId>
            <ArticleId IdType="pubmed">26113309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krizkova S, Kepinska M, Emri G, Rodrigo MA, Tmejova K, Nerudova D, Kizek R, Adam V. Microarray analysis of metallothioneins in human diseases–A review. J Pharm Biomed Anal. 2016;117:464–473. doi:10.1016/j.jpba.2015.09.031. PMID: 26454339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpba.2015.09.031</ArticleId>
            <ArticleId IdType="pubmed">26454339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leierer J, Rudnicki M, Braniff SJ, Perco P, Koppelstaetter C, Muhlberger I, Eder S, Kerschbaum J, Schwarzer C, Schroll A, et al. Metallothioneins and renal ageing. Nephrol Dial Transplant. 2016;31(9):1444–1452. 10.1093/ndt/gfv451. PMID: 26908771.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ndt/gfv451</ArticleId>
            <ArticleId IdType="pubmed">26908771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev. 2012;246(1):379–400. doi:10.1111/j.1600-065X.2012.01099.x. PMID: 22435567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-065X.2012.01099.x</ArticleId>
            <ArticleId IdType="pubmed">22435567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749–759. doi:10.1038/nri1703. PMID: 16175180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri1703</ArticleId>
            <ArticleId IdType="pubmed">16175180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CH, Jeon YT, Kim SH, Song YS. NF-kappaB as a potential molecular target for cancer therapy. Biofactors. 2007;29(1):19–35. doi:10.1002/biof.5520290103. PMID: 17611291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/biof.5520290103</ArticleId>
            <ArticleId IdType="pubmed">17611291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bayoumi AS, Sayed A, Broskova Z, Teoh JP, Wilson J, Su H, Tang YL, Kim IM. Crosstalk between Long Noncoding RNAs and MicroRNAs in Health and Disease. Int J Mol Sci. 2016;17(3):356. doi:10.3390/ijms17030356. PMID: 26978351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms17030356</ArticleId>
            <ArticleId IdType="pmc">PMC4813217</ArticleId>
            <ArticleId IdType="pubmed">26978351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raitoharju E, Seppala I, Oksala N, Lyytikainen LP, Raitakari O, Viikari J, Ala-Korpela M, Soininen P, Kangas AJ, Waldenberger M, et al. Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways underlying metabolic syndrome: the cardiovascular risk in Young Finns Study. Mol Cell Endocrinol. 2014;391(1–2):41–49. 10.1016/j.mce.2014.04.013. PMID: 24784704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mce.2014.04.013</ArticleId>
            <ArticleId IdType="pubmed">24784704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plaisance-Bonstaff K, Renne R. Viral miRNAs. Methods Mol Biol. 2011;721:43–66. doi:10.1007/978-1-61779-037-9_3. PMID: 21431678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-61779-037-9_3</ArticleId>
            <ArticleId IdType="pubmed">21431678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Wu Y, Sun Z, Wang R, Ma D. MicroRNA376a inhibits cell proliferation and invasion in glioblastoma multiforme by directly targeting specificity protein 1. Mol Med Rep. 2018;17(1):1583–1590. doi:10.3892/mmr.2017.8089. PMID: 29257212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/mmr.2017.8089</ArticleId>
            <ArticleId IdType="pmc">PMC5780098</ArticleId>
            <ArticleId IdType="pubmed">29257212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng Y, Yin L, Chen H, Yang S, Pan C, Lu S, Miao M, Jiao B. miR-376a suppresses proliferation and induces apoptosis in hepatocellular carcinoma. FEBS Lett. 2012;586(16):2396–2403. doi:10.1016/j.febslet.2012.05.054. PMID: 22684007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2012.05.054</ArticleId>
            <ArticleId IdType="pubmed">22684007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro E, Levine AJ, Bernardini S, Garabadgiu AV, Melino G, Candi E. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene. 2014;33(44):5173–5182. doi:10.1038/onc.2013.451. PMID: 24166498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2013.451</ArticleId>
            <ArticleId IdType="pubmed">24166498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Cong W, Wu G, Ju X, Li Z, Duan X, Wang X, Gao H. MiR-376a suppresses the proliferation and invasion of non-small-cell lung cancer by targeting c-Myc. Cell Biol Int. 2018;42(1):25–33. doi:10.1002/cbin.10828. PMID: 28741879.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cbin.10828</ArticleId>
            <ArticleId IdType="pubmed">28741879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Jiang F, Xiong Y, Cheng X, Qiu Z, Song R. LncRNA TTN-AS1 sponges miR-376a-3p to promote colorectal cancer progression via upregulating KLF15. Life Sci. 2020;244:116936. doi:10.1016/j.lfs.2019.116936. PMID: 31610194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2019.116936</ArticleId>
            <ArticleId IdType="pubmed">31610194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Jing SY, Liu N, Han S, Yang YK, Han MY, Yan CX. MiR-376a-3p alleviates the development of glioma through negatively regulating KLF15. Eur Rev Med Pharmacol Sci. 2020;24(22):11666–11674. doi:10.26355/eurrev_202011_23811. PMID: 33275234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.26355/eurrev_202011_23811</ArticleId>
            <ArticleId IdType="pubmed">33275234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou G, Jiang H, Ma L. MicroRNA376a inhibits cell proliferation and invasion in osteosarcoma via directly targeting SATB1. Mol Med Rep. 2018;18(3):3521–3528. doi:10.3892/mmr.2018.9344. PMID: 30085330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/mmr.2018.9344</ArticleId>
            <ArticleId IdType="pubmed">30085330</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
